What the Evidence Actually Shows — Not What the Label Claims

The short version

EpiPure Peptides is a reading room, not a store. It exists to say, plainly, what the published research does and does not establish about four research peptides — synthetic chains of amino acids studied in laboratories, animal models, and (for two of the four) human clinical trials. The four are ipamorelin, KPV, tesamorelin, and tirzepatide, and they are not variations on one theme: one is a growth-hormone secretagogue, one is an anti-inflammatory tripeptide, one is an approved GHRH-axis drug, and one is an approved dual-hormone-receptor drug for metabolic disease.

What ties them together on this desk is not their pharmacology. It is a question this site asks about every one of them before it asks anything else: what is the actual evidence quality, and is the material anyone can obtain outside a clinical trial even verified to be what it claims to be? Two of the four (tesamorelin, tirzepatide) are FDA-approved prescription medicines with large trial programs. Two (ipamorelin, KPV) have never been approved for any human use, and their entire efficacy case rests on animal models, cell culture, or a single small trial that did not meet its goal.

This site does not sell anything, does not recommend a dose, and does not tell anyone what to do with this information. It cites its sources, flags where a claim comes from one study instead of ten, and says so when the honest answer is we don't actually know.

What are research peptides?

Peptides are short chains of amino acids — smaller than proteins, but built from the same building blocks. "Research peptide" is the label suppliers use for compounds sold explicitly for laboratory use, not human consumption; it is a regulatory and marketing category as much as a chemical one. Some research peptides eventually clear clinical trials and become approved drugs (tesamorelin and tirzepatide both did). Others stay permanently in the research-only category because no sponsor has run — or in some cases, because a sponsor ran and failed — the trials needed for approval (ipamorelin's one placebo-controlled human trial missed its primary endpoint; KPV has never been tested in a human trial at all).

That distinction matters more than most marketing acknowledges. A compound sold as "research-grade" carries none of the quality assurance that accompanies an approved pharmaceutical: no mandated purity testing, no batch-to-batch identity verification, no chain-of-custody guarantee that what is in the vial matches what is on the label. This site treats that gap — between what has been studied and what is actually being sold — as the central fact a skeptical reader needs, not a footnote.

Why purity and sourcing get equal billing with the pharmacology

Most peptide content online reads like an advertisement: mechanism, then benefits, then, several screens down, a disclaimer. This desk inverts that order on purpose. Before describing what a compound does, each page on EpiPure Peptides asks how solid the underlying evidence is — human RCT, animal model, or cell culture — and separately, whether "research-grade" material sold outside a clinical trial has any verified relationship to what was actually studied.

Those are two different problems that get conflated constantly. A compound can have excellent clinical trial data (tirzepatide does) and still be sold, under other names or dosing claims, by unregulated suppliers whose product has never been independently assayed. A compound can have almost no human data at all (KPV, ipamorelin) and still be marketed with confident claims lifted from a rodent study or a mechanism paper. Neither situation is disclosed by the seller. Both are disclosed here, compound by compound, with the citation attached to every claim that needs one. This is the Research Peptide Fundamentals angle — purity, sourcing, and evidence quality, read with the same skepticism regardless of which compound is on the page.

How to use this desk

Each compound page follows the same discipline: what the compound is, chemically; how it is proposed to work, mechanistically; what the actual trial or animal literature shows, cited by number; what people in research-use communities report anecdotally (clearly labeled as such, never as evidence); and cited cautions — drawn from clinical findings where they exist, and from the documented gaps and controversies in the literature where they do not. The comparison page lines up all four on evidence maturity, regulatory status, and mechanism. The FAQ answers the specific questions people bring to search engines about each compound. Every citation across the site resolves on the shared references page. Nothing here recommends a human dose, a supplier, or a course of action.